Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: MYELO THERAPEUTICS GMBH
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-05-01 to 2023-01-31
Current total value of award: $6508796
Description: IPP: DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME